肺部疾病是全球性的重大健康问题，影响着世界各地数以百万计的人。最近的研究突出了线粒体质量控制在呼吸相关疾病中的关键作用，包括慢性阻塞性肺疾病（COPD）、肺癌和特发性肺纤维化（IPF）。本综述总结了有关线粒体质量控制在这些疾病中的最新发现，并讨论了潜在的治疗策略。线粒体是能量生产和其他细胞过程的重要细胞器，其功能失调与各种疾病有关。线粒体的质量控制涉及到包括线粒体自噬、线粒体生物发生、融合/分裂动力学和基因表达调控在内的复杂通路系统。在COPD和肺癌中，线粒体质量控制经常参与疾病发展，通过影响氧化应激和细胞凋亡。在IPF中，它似乎参与细胞衰老的过程，参与疾病过程。线粒体质量控制是肺部疾病治疗的一个有前景的靶点。然而，关于不同病理过程存在着对于线粒体自噬在肺癌中的作用等相互矛盾的报道，这给针对线粒体质量控制药物的研究带来了困难。此外，在生理状态下，线粒体质量控制过程之间似乎存在微妙的平衡。新的证据表明，诸如PTEN诱导的潜在激酶1（PINK1）、帕尔金RBR E3泛素蛋白连接酶（PRKN）、粒内膜螺旋蛋白相似蛋白1（DRP1）、过氧化物酶体增殖物激活受体γ共激活因子1-α（PGC1-α）及其影响的信号通路，在呼吸相关疾病中发挥着重要作用。针对这些分子和通路可能有助于开发有效的肺部疾病治疗方法。总之，线粒体质量控制在肺部疾病中的参与为疾病治疗提供了一个有前景的新途径。需要进一步研究以更好地了解呼吸道疾病发病机制的复杂性，并开发出有针对性的治疗方法，以改善临床预后。版权所有 © 2023 刘、王、熊、张、张、刘、熊、李和何

Lung diseases are a major global health problem, affecting millions of people worldwide. Recent research has highlighted the critical role that mitochondrial quality control plays in respiratory-related diseases, including chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF). In this review, we summarize recent findings on the involvement of mitochondrial quality control in these diseases and discuss potential therapeutic strategies. Mitochondria are essential organelles for energy production and other cellular processes, and their dysfunction is associated with various diseases. The quality control of mitochondria involves a complex system of pathways, including mitophagy, mitochondrial biogenesis, fusion/fission dynamics, and regulation of gene expression. In COPD and lung cancer, mitochondrial quality control is often involved in disease development by influencing oxidative stress and apoptosis. In IPF, it appears to be involved in the disease process by participating in the cellular senescence process. Mitochondrial quality control is a promising target for therapeutic interventions in lung diseases. However, there are conflicting reports on different pathological processes, such as the role of mitochondrial autophagy in lung cancer, which pose difficulties in the study of targeted mitochondrial quality control drugs. Additionally, there seems to be a delicate balance between the mitochondrial quality control processes in the physiological state. Emerging evidence suggests that molecules such as PTEN-induced putative kinase 1 (PINK1), parkin RBR E3 ubiquitin protein ligase (PRKN), dynamin-related protein 1 (DRP1), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α), as well as the signaling pathways they affect, play an important role in respiratory-related diseases. Targeting these molecules and pathways could contribute to the development of effective treatments for lung diseases. In conclusion, the involvement of mitochondrial quality control in lung diseases presents a promising new avenue for disease treatment. Further research is needed to better understand the complex mechanisms involved in the pathogenesis of respiratory diseases and to develop targeted therapies that could improve clinical outcomes.Copyright © 2023 Liu, Wang, Xiong, Zhang, Zhang, Liu, Xiong, Li and He.